護城河比較
最多三家已涵蓋的公司，逐項對照。每一項判斷都是人工編輯的判斷，而非公司揭露的數字——而且每一項都附有其引用依據。
| Wiwynn | Eli Lilly and Company | |
|---|---|---|
| 護城河評級 | 窄 The 2025 annual report (published 2026-04-30) shows a real but shallow position: products deployed in "more than 750 hyperscale data centers" and, on the Company's own internally assessed shipment volume, "more than 10% of global server shipments and nearly 30% of global ODM-Direct server shipments" in 2025 — while the same report's own list of negative factors names "Excessive concentration of customers" and a market "getting more and more competitive", discloses three customers at 41.48%, 26.03% and 10.43% of 2025 net sales, and reports 2025 gross profit up 109.77% against revenue up 163.68% for an 8.3% gross margin. Defensible incumbency, not a durable one. | 寬 Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| 護城河類型 | 轉換成本 The report's "Competitive niche" section locates the advantage in the customer program rather than in IP or unit cost: "highly customized solutions for hyperscale data centers", "end-to-end technical integration capabilities ranging from server design and system integration to large-scale L10/L11 rack-level delivery", and a one-stop service "covering product design, integration, optimization, deployment, and after-sales services" across a base of more than 750 hyperscale data centers. Every advantage the section claims is about integration work and customer proximity, none about patents or proprietary silicon, and an 8.3% gross margin is not the profile of a cost advantage; what is left is the friction in an installed, co-designed rack program. | 無形資產與智慧財產 Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| 領先地位 | 並列領先者 The report claims "nearly 30% of global ODM-Direct server shipments" for 2025 on internally assessed volume, against an IDC Worldwide Quarterly Server Tracker base of approximately 7.7 million ODM-Direct units within roughly 16.78 million total 2025 server shipments — yet describes the Company only as "one of the major suppliers to international hyperscale data centers". Among the largest in its segment; the report makes no claim to be first. | 並列領先者 Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| 定價權 | 弱 2025 gross margin was 8.3% and operating margin 6.7%; gross profit rose 109.77% while revenue rose 163.68%, so the margin narrowed as volume grew. The report discloses three customers at 41.48%, 26.03% and 10.43% of 2025 net sales, lists "Excessive concentration of customers" among its negative factors, and explains its main-supplier table with "The suppliers are designated by customers." | 中等 Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| 綜述 | Wiwynn sells ODM-Direct — it designs and builds cloud and AI server systems to hyperscale operators' specifications rather than shipping a branded product — and the 2025 annual report grounds its edge in that relationship: "highly customized solutions", integration "from server design and system integration to large-scale L10/L11 rack-level delivery", Open Compute Project participation described as "a core competitive advantage in marketing to global hyperscale data centers", and products deployed in more than 750 hyperscale data centers as of the end of 2025. The report also says that high integration and testing abilities "increases the threshold of vendors in the assembly industry and creates entry barriers". Against that, the same report lists excessive customer concentration and an increasingly competitive market as its negative factors, discloses customers at 41.48%, 26.03% and 10.43% of 2025 net sales, explains its main-supplier table with "The suppliers are designated by customers", and reports an 8.3% gross margin on 2025 revenue of NT$950.66bn. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| 產業鏈位置 | The report's cloud/AI-server value-chain diagram places system assembling in the midstream and "Direct sales from original manufacturers" downstream selling to cloud service providers; Wiwynn describes itself as providing "IT equipment and rack system integration service to hyperscale data centers". 82.12% of 2025 revenue came from America. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| 產品（市佔 / 門檻） |
|
|
| 長週期投票 | +0.05 權重 0.20 · 群體判斷 bearish 編輯先驗，未經回測。 | +0.30 權重 0.20 · 群體判斷 neutral 編輯先驗，未經回測。 |